Practical HPLC in Pharmaceutical Analysis
| Type |
Course |
| Language |
English |
| Date |
August 17, 2009
from
08:30 am
to
05:00 pm
|
| Venue |
Crowne Plaza Hotel - The Hamilton
1001 14th St NW
Washington, DC,
DC
20005
US
|
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
American Chemical Society
1155 Sixteenth Street, NW
Washington,
DC
20036
US
(800) 227-5558
shortcourses@acs.org
|
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
Analytical procedures are used to assure that the drug product meets applicable standards of identity, strength, quality, and purity during its expiration dating. The majority of analytical methods used in pharmaceutical development are HPLC analyses. cGMPs require stability indicating methods to monitor the drug product’s stability profiles. Therefore, method development and validation significantly impact the drug development process. Additional expectations are also placed on the monitoring of impurities and degradation products.
This course focuses on reversed-phase analysis of drug substances and drug products (small molecule). It will discuss forced degradation strategies to develop stability-indicating analytical procedures. A review of ICH guidelines on validation and impurities will be done to help Pharmaceutical Manufacturers to gain better understanding of method validation by phases of drug development and regulatory expectations through a review of warning letters.
Key Topics
* Design your forced degradation studies to support method specificity
* Review cGMP regulations that govern the pharmaceutical laboratory
* Understand ICH regulations surrounding method validation and stability-indicating procedures (Q2A&B)
* Impact of developing stability indicating methods
* Understand Q3 for impurities monitoring
Speakers
Kim Huynh-Ba is the Technical Director of Pharmalytik Consulting and Training Services (www.pharmalytik.com). With over twenty years of experience in various analytical areas of pharmaceutical development and a primary focus in stability sciences, she specializes in analytical development, stability, outsourcing and technology transfer management. She has been involved with several projects harmonizing and optimizing analytical best practices in several companies, including those under Consent Decree.
Kim has authored numerous technical publications and is invited as a frequent speaker at national and international conferences. Since 2001, she has conducted training activities on cGMP compliance and quality issues for national organizations such as ACS, AAPS, IIR, SWE, IVT and CBI. She is also the founder of the AAPS Stability Focus Group, and is an active member of AAPS, PSDG, as well as serving on the Governing Board of Eastern Analytical Symposium (EAS). She also is EAS 2008 Short Course Chair and AAPS 2008 APQ Distance Learning Chair.
Session titles
I. Regulatory Aspects in Pharmaceutical Testing
* Impact of analytical testing in the drug development process
* cGMP requirements for analytical test methods
* Review ICH Q2 A&B guidelines for method development/validation
* Design method specificity through forced degradation activities
II. Key Concepts in Reversed-phase LC
* An overview of key HPLC concepts
* Mobile phase parameters (pH) and method orthogonality
* How to select HPLC columns to support specificity
III. Best Practices in HPLC Method Development
* Stress studies to challenge stability-indicating power of analytical procedures
* Review strategies and modern method development trends
* Method optimization to meet ICH reporting guidelines
* Phase-appropriate method development and validation
IV. Managing Validation Data for Quality and Compliance
* Recent FDA 483 observations related to analytical method validation
* Overview of Q3 for impurities monitoring
* System suitability of HPLC test methods
More information about this event…